$5.58
+0.21 (+3.91%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SVRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 expanded access · 8 with posted results
Held by 9 tracked-famous managers (MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, +4 more) · FINRA short interest 20.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).NCT06431776DLCOOpen-label · Treatment | Phase 3 | Recruiting | Drug: Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | 5 | Jun 2027 | ≤ 314 d | 2026-02-19 |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293results2025-08-07Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Molgramostim, Placebo, Molgramostim Open-label | Autoimmune Pulmonary Alveolar Proteinosis | 164 | 2023-11-30actual | — | 2025-08-07 |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisNCT03482752results2024-07-03Number of Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: SAV006-03 was initiated before the evaluation of the IMPALA study (NCT02702180) results. Considering these results and authority advice there would not be adequate efficacy and safety data from SAV006-03 and the study was terminated. | Drug: Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | 60 | 2021-01-14actual | — | 2024-07-03 |
| Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial InfectionNCT03597347results2021-10-11Number of Participants With Sputum NTM Culture Conversion to NegativeNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Recruitment for trial stopped early due to limitations from COVID-19, additionally changes in the standard of care for CF patients during the study period resulted in confounding of the primary endpoint. | Drug: Molgramostim nebulizer solution · Device: PARI eFlow nebulizer system | Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF) | 14 | 2020-10-02actual | — | 2023-01-10 |
| AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic FibrosisNCT03181932results2021-11-05Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent PredictedRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Vancomycin inhalation powder, Placebo inhalation powder, Vancomycin inhalation powder | MRSA, Cystic Fibrosis | 188 | 2020-07-28actual | — | 2022-12-16 |
| Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) InfectionNCT03421743results2024-07-03Number of Participants With Sputum Culture Conversion to NegativeNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Inhaled molgramostim, Antimycobacterial regimen | Mycobacterium Infections, Nontuberculous | 32 | 2019-10-15actual | — | 2024-07-03 |
| Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar ProteinosisNCT02702180results2022-04-15Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of TreatmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Molgramostim, Placebo · Device: PARI eFlow nebulizer system | Autoimmune Pulmonary Alveolar Proteinosis | 139 | 2019-04-19actual | — | 2023-04-12 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult SubjectsNCT02468908Number and severity of treatment-emergent Adverse Events (AEs) following single and multiple inhaled doses of molgramostimRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Molgramostim, Placebo | Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis, Acute Respiratory Distress Syndrome | 42 | Oct 2015actual | — | 2017-02-23 |
| Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis PatientsNCT01746095results2020-01-13Change From Baseline in MRSA Sputum Density.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Vancomycin hydrochloride inhalation powder, Placebo inhalation powder | Cystic Fibrosis | 87 | Nov 2014actual | — | 2020-01-13 |
| Inhaled Vancomycin Tolerability, Safety and PharmacokineticsNCT01537666results2014-03-04Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study Drug)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AeroVanc, IV vancomycin hydrochloride | Healthy, Cystic Fibrosis | 25 | Mar 2012actual | — | 2014-03-31 |
| Molgramostim Nebulizer Solution Expanded Access Program ProtocolNCT06546098expanded access | — | Available | Drug: Molgramostim nebulizer solution | Autoimmune Pulmonary Alveolar Proteinosis | — | — | — | 2026-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19